|
SAN
DIEGO, March 11 /PRNewswire-FirstCall/ -- Nanogen,
Inc. (Nasdaq: NGEN), developer of advanced diagnostic
products, announced today that it was issued U.S.
Patent No. 6,864,071, "Multiplex amplification
and separation of nucleic acid sequences using ligation-dependent
strand displacement amplification and bioelectronic
chip technology," by the U.S. Patent and Trademark
Office. The '071 patent relates to amplifying and
analyzing multiple samples of nucleic acid using ligation-based
strand displacement amplification (SDA) technologies.
The intellectual property pertains to research Nanogen
conducted in collaboration with Becton Dickinson and
increases Nanogen's portfolio of technologies for
multiplex amplification on a chip.
The combination of
SDA and Nanogen chip technologies makes it possible
to conduct multiplex amplification, detection and
analysis of multiple samples within a single electronic
microarray. Unlike techniques that rely on thermal
cycling, SDA is an isothermal amplification process
that utilizes a series of primers, DNA polymerase
and a restriction enzyme to exponentially amplify
the target nucleic acid sequence. The devices and
methods of Nanogen's invention may be useful in a
variety of applications, including disease diagnostics,
genetic analyses, drug discovery, pharmacogenomics,
and agricultural and environmental applications.
This new patent expands
Nanogen's intellectual property portfolio to include
113 patents issued in the U.S.
About Nanogen, Inc.
Nanogen's advanced
diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose
and treat disease. Research and clinical reference
labs use the highly accurate and reliable NanoChip(R)
Molecular Biology Workstation, NanoChip(R) Electronic
Microarray and broad suite of analyte specific reagents
to develop tests to detect infectious diseases, drug
toxicity and mutations associated with cancer, cardiovascular
and genetic diseases. The next generation instrument
system, the NanoChip(R) 400, is expected to be available
in 2005. Nanogen's subsidiary SynX offers a line of
point-of-care diagnostic tests and is building expertise
in cardiac related health conditions. Nanogen's ten
years of pioneering research involving nanotechnology
may also have future applications in medical diagnostics,
biowarfare and other industries. For additional information
please visit Nanogen's website at www.nanogen.com.
SOURCE
Nanogen, Inc.
/CONTACT: Robert Saltmarsh, Chief Financial Officer
of Nanogen, Inc.,
+1-858-410-4600; or Media & Investor Relations,
Pam Lord of Atkins +
Associates, +1-858-527-3494, plord@irpr.com, for Nanogen,
Inc./
/Web site: http://www.nanogen.com /
(NGEN)
|
